Loading clinical trials...
Loading clinical trials...
Quantitative Study on HRCT Phenotype of the GOLD COPD Assessment Staging
To explore the HRCT phenotype of the combined COPD assessment staging system
HRCT can be rapidly and safely deployed has enabled COPD research to move beyond FEV1 by facilitating and amplifying clinical phenotyping measurements, providing quantitative information, and detecting significant responses to therapy even in the absence of significant FEV1 improvements. We explore the HRCT phenotype of the combined COPD assessment staging system,and found that: 1. Airway remodeling occurs in COPD patients. CT shows varying degrees of bronchial wall thickness, area increasing and emphysema as the new GOLD classification Group A-D arising. 2. The GOLD Combined assessment staging system helps doctors choose an individualized treatment for the COPD patients
Age
40 - 80 years
Sex
ALL
Healthy Volunteers
Yes
Peking University Third Hospital
Beijing, China
Start Date
July 1, 2013
Primary Completion Date
November 30, 2014
Completion Date
November 30, 2014
Last Updated
July 8, 2021
150
ACTUAL participants
Lead Sponsor
Peking University Third Hospital
NCT07477600
NCT05878769
NCT06717659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions